Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements on September 11, 2026, to raise capital through a private placement. The company agreed to sell an aggregate of 2,703,727 shares of common stock to certain investors. The total purchase price for these shares was $2,838,911, resulting in a price of $1.05 per share. The transaction closed on the same day, September 11, 2026.
The financing included a component involving the company’s Chief Executive Officer, Jerry (Junli) He. Mr. He purchased 683,725 shares of common stock. These shares were issued in exchange for the conversion and cancellation of outstanding bridge promissory notes. The notes were issued to Mr. He on April 14, 2026, May 13, 2026, and July 16, 2026, with a total outstanding principal and accrued interest of $717,911. The notes were cancelled in full upon the closing of the transaction.
The shares issued to the investors were sold without registration under the Securities Act. The company relied on exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors. The company also relied on similar exemptions under applicable state laws.
